Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 8/20 | 0.38 |
| ▸ | RARB | P10826 | 2/20 | 0.38 |
| ▸ | RARG | P13631 | 2/20 | 0.38 |
| ▸ | RARA | P10276 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21777035 | 0.77 | NOTUM (0.63) | NOTUMMETAP2PTGS1PTGS2 | |
| SCHEMBL28093367 | 0.76 | NOTUM (0.55) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL23451691 | 0.76 | NOTUM (1.00) | NOTUMKDM4EALDH1A1MAPT | |
| SCHEMBL23451975 | 0.73 | METAP2 (0.63) | NOTUMNPC1RAB9ASMN1; SMN2METAP2 | |
| SCHEMBL21776977 | 0.73 | NOTUM (0.47) | NOTUMSNCA | |
| SCHEMBL30412738 | 0.73 | NOTUM (0.47) | NOTUMSNCA | |
| SCHEMBL8982307 | 0.72 | NOTUM (0.49) | NOTUMKDM4EALDH1A1MAPTRARB | |
| SCHEMBL28093368 | 0.71 | NOTUM (0.50) | NOTUMNPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL18429566 | 0.69 | NOTUM (0.50) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL23451538 | 0.68 | NOTUM (0.57) | NOTUMKDM4ENPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| EP-3843844-A1 | COMPOUNDS | UCL Business Ltd (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | NOTUM 1/4885KDM4E 3907/4885NPC1 51/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | NOTUM 5/4885KDM4E 4149/4885NPC1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.